Vaginal News and Research

RSS

EC approves Pfizer's Vyndaqel to treat Transthyretin Familial Amyloid Polyneuropathy

Pfizer announced today that the European Commission has approved Vyndaqel (tafamidis) for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy.

17 Nov 2011

New possibilities for relief from digestive diseases

As a researcher in neurogastroenterology for 40 years, professor Khalil Bitar has spent his professional life studying the causes of perplexing and what frequently become embarrassing problems for humans—issues such as constipation, diarrhea and colon disease.

17 Nov 2011

First clinical trial of dapivirine-maraviroc ring to treat HIV in women

In the first clinical trial of a vaginal ring combining two antiretroviral (ARV) drugs, researchers from the Microbicide Trials Network (MTN) are collaborating with the International Partnership for Microbicides (IPM) to evaluate whether the ring is safe for use in women.

16 Nov 2011

Viewpoints: Conservative legal path on health law; Romney's plans for Medicare and vets; States moving on reform

A federal appeals court in the District of Columbia endorsed the constitutionality of health care reform this week in an opinion as notable for its authorship as for its legal reasoning. The majority opinion in the 2-to-1 decision was written by Judge Laurence Silberman, a stalwart of conservative jurisprudence whose views are said to be enormously influential in conservative legal circles.

14 Nov 2011

First-ever phase 1 clinical trial of rectal HIV-prevention drug

A topically applied microbicide gel containing a potent anti-HIV drug has been found to significantly reduce infection when applied to rectal tissue that was subsequently exposed to HIV in the laboratory, according to a new study by the UCLA AIDS Institute.

9 Nov 2011

Malpractice charges work way slowly through legal system, if at all

As hospitals and doctors try to implement new ways of preventing lawsuits, scrutiny of the system continues around the country.

7 Nov 2011

Columbia Laboratories third quarter total net revenues decrease to $4.9 million

Columbia Laboratories, Inc. today reported financial results for the three- and nine-month periods ended September 30, 2011.

3 Nov 2011

UC Merced professor designs powerful chemical inhibitor against HIV

In a significant step toward reducing the threat of HIV, UC Merced Professor Patricia LiWang has designed what may be the most effective chemical inhibitor against infection of the virus.

3 Nov 2011

Oral hormonal contraceptives linked to blood clots: Study

A new study has shown that women who use new type of contraceptive pills are twice as likely to develop life threatening blood clots as those who take older versions. Oral hormonal contraceptives have been known to increase the risk of a blood clot in deep leg veins, known as venous thromboembolism (VTE). These can prove fatal if they travel to the lungs. But, researchers at the University of Copenhagen, Denmark, found the “third-generation” pills are doubly harmful than the older versions.

30 Oct 2011

Anti-HIV vaginal gel could also reduce genital herpes by half: Study

The study appears this week in the journal Cell Host & Microbe that tested the gel on women in South Africa (where the risk of HIV and herpes is great) found that the anti-HIV/AIDS drug tenofovir reduced herpes infections by 51% and HIV infections by 39%.

24 Oct 2011

World's largest study of the fear of childbirth

A few women are so afraid of giving birth that they avoid becoming pregnant or seek an abortion, even though they want to have children. This fear is related to several serious conditions such as prolonged labour, a greater need for pain relief during labour and an increased risk of an emergency C-section.

21 Oct 2011

Effective ways to reduce risk of vaginal yeast infection

Vaginal thrush is one of the most popular topics on NHS Choices website. This common yeast infection affects around 75% (three-quarters) of women at some point. Up to half of these will have thrush more than once.

21 Oct 2011

Tenofovir gel shows promise against HSV infection

HIV infection is commonly associated with other sexual infections, such as herpes simplex virus (HSV). Infection with HSV facilitates the risk of HIV infection and negatively impacts the clinical course of HIV disease. Therefore, it would be highly beneficial to identify multi-faceted microbicide compounds that are efficient against HIV-1 and other sexually transmitted infections.

20 Oct 2011

New guidelines for prevention and early detection of cervical cancer

The American Cancer Society (ACS), the American Society for Colposcopy and Cervical Pathology (ASCCP), and the American Society for Clinical Pathology (ASCP) have proposed new guidelines for the prevention and early detection of cervical cancer.

20 Oct 2011

AAGL to showcase innovative surgical approaches, teaching tools at 40th Global Congress

Technology has radically changed the way surgeons practice medicine, and nowhere is this more evident than in the field of gynecologic endoscopy. AAGL, the oldest professional organization devoted to teaching minimally invasive treatment for women's health problems, will showcase a number of innovative surgical approaches and teaching tools among the hundreds of postgraduate courses and practice labs offered at its annual Global Congress, November 6-11, 2011 at the Westin Diplomat in Hollywood, FL.

19 Oct 2011

Diethylstilbestrol in utero affects immune system of the fetus

A synthetic estrogen — diethylstilbestrol (DES), prescribed to women in the 1940s, 1950s, and 1960s to prevent miscarriages, had serious, untoward effects in daughters of these women, including the development of a rare type of cancer of the uterus.

11 Oct 2011

Pregnant mums taking miscarriage prevention drug decades ago may have put their girls at risk of infertility and cancers

A new study reveals that a drug that was taken by millions of pregnant women decades ago to prevent miscarriage and complications has put their daughters at higher risk for breast cancer and other health problems. The study shows that many of these daughters are now over 40 and may not even know of their risk if their mothers never realized or told them they had used the drug, a synthetic estrogen called DES or Diethyl stilbesterol.

6 Oct 2011

FDA clears Nucletron's new VCMC Applicator for gynecologic cancers

During the first day of the annual conference for the American Society for Radiation Oncology (ASTRO) in Miami, Nucletron, an Elekta company, today announced that it has received FDA 510(k) clearance for its new Vaginal CT/MR Multi Channel (VCMC) Applicator, offering a brachytherapy solution that enables very precise dose delivery for gynecologic cancers.

From Elekta 3 Oct 2011

Microbicide Trials Network stops tenofovir arm of study after findings show drug less effective than anticipated

"The Microbicide Trials Network (MTN), which is funded by the U.S. National Institutes of Health, on Wednesday announced that it decided to stop one arm of a study involving more than 5,000 women in South Africa, Zimbabwe, and Uganda" after "an interim review of the ongoing trial by an independent monitoring board found that the drug tenofovir when used as pre-exposure prophylaxis (PrEP) had less effect in protecting women than anticipated," Science Magazine's "Science Insider" blog reports.

30 Sep 2011

Oral tenofovir discontinued in HIV clinical trial

A large-scale clinical trial evaluating whether daily use of an oral tablet or vaginal gel containing antiretroviral drugs can prevent HIV infection in women is being modified because an interim review found that the study cannot show that one of the study products, oral tenofovir, marketed under the trade name Viread, is effective.

29 Sep 2011